Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Parallel Group, Multi-center Single Dose Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36

NCT01372124 is registered in ClinicalTrials.gov with TME Pharma AG as lead sponsor.

NCT NCT01372124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01372124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Parallel Group, Multi-center Single Dose Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36
Lead sponsor
TME Pharma AG
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2011
Completion date
October 31, 2012
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment